Detalles de la búsqueda
1.
Translating trial results into interpretable risk estimates: Systematic analysis of cardiorenal outcome trials of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors.
Nutr Metab Cardiovasc Dis
; 34(5): 1129-1133, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38336546
2.
Intensive glucose control and recurrent cardiovascular events: 14-year follow-up investigation of the ACCORDION study.
Diabetes Metab Res Rev
; 39(5): e3634, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-36905248
3.
Non-inferiority and clinical superiority of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: Systematic analysis of cardiorenal outcome trials in type 2 diabetes.
Diabetes Obes Metab
; 24(8): 1598-1606, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35491523
4.
Cardiovascular effects of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: The P value and beyond.
Diabetes Obes Metab
; 23(7): 1685-1691, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33764645
5.
Patterns of multimorbidity and risk of severe SARS-CoV-2 infection: an observational study in the U.K.
BMC Infect Dis
; 21(1): 908, 2021 Sep 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34481456
6.
Ethnic minorities and COVID-19: examining whether excess risk is mediated through deprivation.
Eur J Public Health
; 31(3): 630-634, 2021 07 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-33744940
7.
Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes.
Ann Intern Med
; 172(8): 541-552, 2020 04 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-32203984
8.
Number needed to treat in cardiovascular outcome trials of glucagon-like peptide-1 receptor agonists: A systematic review with temporal analysis.
Diabetes Obes Metab
; 22(9): 1670-1677, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32372425
9.
Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A systematic review and network meta-analysis.
Diabetes Obes Metab
; 22(7): 1035-1046, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32077218
10.
Efficacy of low- and very-low-energy diets in people with type 2 diabetes mellitus: A systematic review and meta-analysis of interventional studies.
Diabetes Obes Metab
; 21(7): 1695-1705, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30924575
11.
Effect of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on time to outcome in type 2 diabetes cardiorenal outcome trials.
Diabetes Metab Syndr
; 18(2): 102945, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38262118
12.
Microvascular Disease and Risk of Cardiovascular Events and Death From Intensive Treatment in Type 2 Diabetes: The ACCORDION Study.
Mayo Clin Proc
; 96(6): 1458-1469, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33952397
13.
Association Between Accelerometer-Assessed Physical Activity and Severity of COVID-19 in UK Biobank.
Mayo Clin Proc Innov Qual Outcomes
; 5(6): 997-1007, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34430796
14.
Association of Timing and Balance of Physical Activity and Rest/Sleep With Risk of COVID-19: A UK Biobank Study.
Mayo Clin Proc
; 96(1): 156-164, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33413813
15.
Comment on Baranova et al. Causal Associations Between Basal Metabolic Rate and COVID-19. Diabetes 2023;72:149-154.
Diabetes
; 72(8): e6-e7, 2023 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37471596
16.
Use of Metformin and Cardiovascular Effects of New Classes of Glucose-Lowering Agents: A Meta-analysis of Cardiovascular Outcome Trials in Type 2 Diabetes.
Diabetes Care
; 44(2): e32-e34, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33334809
Resultados
1 -
16
de 16
1
Próxima >
>>